Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(16/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(16/week)
News
United States
(1411/week)
Manufacturing
(719/week)
Energy
(555/week)
Technology
(1432/week)
Alternative Energy
(170/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
SCYNEXIS, Inc.
Feb 13, 2020
SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
Jan 08, 2020
SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
Dec 16, 2019
SCYNEXIS Appoints Business Development Veteran Philippe Tinmouth to its Board of Directors
Dec 12, 2019
SCYNEXIS Announces Closing of $35 Million Public Offering of Common Stock and Warrants
Nov 14, 2019
SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States
Nov 12, 2019
SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update
Nov 07, 2019
SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303)
Oct 24, 2019
SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date
Oct 02, 2019
SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris
Jul 24, 2019
SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)
Jun 25, 2019
World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019
Jun 14, 2019
SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
May 06, 2019
SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)
Apr 01, 2019
SCYNEXIS, Inc. to Present at Upcoming Investor Conferences
Mar 14, 2019
SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update
Feb 28, 2019
SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019
Jan 30, 2019
SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies
Jan 22, 2019
SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors
Nov 13, 2018
SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update
Oct 15, 2018
SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
Page 1
››
Latest News
May 21, 2024
Mark43 Welcomes Teresa Carlson as Board Observer
May 21, 2024
BAE Systems signs contract with Sweden for new CV90 combat vehicles
May 21, 2024
Enough is Enough! Advance Auto Parts Survey Reveals More Americans will Hit the Road this Summer Due to Air...
May 21, 2024
Immervision Announces Advanced Image Quality Lab in Sofia to Provide Next-Level Imaging Services
May 21, 2024
New Eptura Research Reveals Employee-Led Hybrid Work Models and Connected Technology Drive Highest Return
May 21, 2024
Laser Photonics Launches Next Generation of CleanTech Laser Cleaning Systems
May 21, 2024
Ecolab Releases 2023 Growth & Impact Report, Showcases Progress Toward Creating 2030 Positive Impact
May 21, 2024
LevertonHELM and Mangrove Lithium Sign MoU for Development of Battery-Grade Lithium Refinery in Europe
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events